Overview

* Astrana Q2 2025 revenue rises 35% yr/yr but misses analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 at higher end of co's guidance

* Company completed acquisition of Prospect Health, enhancing growth prospects

Outlook

* Astrana sees Q3 revenue between $925 mln and $965 mln

* Company expects full-year revenue between $3.1 bln and $3.3 bln

* Astrana anticipates Q3 adjusted EBITDA of $65 mln to $70 mln

* Company reiterates full-year guidance including Prospect Health acquisition

Result Drivers

* REVENUE GROWTH - Total revenue increased by 35% year-over-year, driven by effective management of medical cost trends

* TECHNOLOGY PLATFORM - Company's technology-enabled model contributed to strong results, providing real-time visibility into patient health

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $631.44 $638.30

Revenue mln mln (9

Analysts

)

Q2 $49.68

Income mln

from

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Astrana Health Inc ( ASTH ) is $46.00, about 52.6% above its August 6 closing price of $21.81

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)